期刊
PHARMACEUTICALS
卷 15, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/ph15040463
关键词
beta-lactams; beta-lactamase inhibitors; cefiderocol; pharmacokinetics; pharmacodynamics
Bacterial resistance mechanisms are continuously and rapidly evolving, especially for Gram-negative bacteria. The strategy of developing new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has been successful, and data on several compounds are becoming available. Cefiderocol, with its unique mechanism of action, warrants separate discussion.
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据